Piperidines are an important group of heterocyclic compounds in the field of medicinal chemistry owing to the fact that these can frequently be recognized in the structure of numerous naturally occurring alkaloid and synthetic compounds with interesting biological and pharmacological properties. Piperidones were also reported to possess analgesic, 2, 3) anti-inflammatory, 3) central nervous system (CNS), [4] [5] [6] [7] [8] local anaesthetic, 4, 9) anticancer 10) and antimicrobial activity.
11) The earlier reports indicated that the significant biological activities of piperidones were associated with aromatic substituents at 2nd and/or 6th positions. 6, 11) Oximes of the 2,6-disubstituted piperidones were also reported to exhibit antimicrobial, 12) analgesic, 13) local anaesthetic 13) and antifungal activity. 13) The benzimidazole nucleus is widely accepted for its antiallergic and antiasthmatic activity 14, 15) and its derivatives were found to possess diverse biological activities such as antiamoebic, microfilaricidal, antifungal and antiarylthemic. [16] [17] [18] [19] [20] [21] [22] It is well known that in the treatment of parasitic infection, substituted benzimidazoles, mebendazole and febendazole were found to be efficient. 23, 24) Benzoxazole nucleus is also marked for its biological activity. 2-Substituted benzoxazoles have been shown to exert analgesic, 25) fungicidal, insecticidal, nematocidal, 26) potent protease inhibitory, 27) anticancer activities 28) and serve as topoisomerase I poisons. 29) An essential part of the search for new leads in a drug designing programme is the synthesis of new molecules, which are novel yet resemble known biologically active molecules by virtue of the presence of some critical structural features. There are few small heterocyclic molecules, which act as highly functionalized scaffolds and are known pharmacophores of a number of biologically active and medicinally useful molecules. [30] [31] [32] Aiming at extending our knowledge in structure-activity relationship, we considered that it was valuable to synthesis a system which unites biolabile piperidone oximes and benzimidazole and benzoxazole units respectively together to give a compact structure of benzimidazolylethoxypiperidone oximes and benzoxazolylethoxypiperidone oximes. The influence of some structural variations at different pharmacophoric groups in the synthesized compounds towards their biological activities was evaluated.
In the course of broad programme in developing biologically active molecules, we have recently reported the synthesis of 2,6-diarylpiperidin-4-one derivatives and evaluated their biological importance and also a reagent for effecting functional group interconversion. [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] 
MATERIALS AND METHODS
The course of reaction and purity were ascertained by performing TLC. Melting points were determined in open capillaries and are uncorrected. IR spectra were recorded in Perkin-Elmer 297 spectrophotometer with KBr and only noteworthy absorption levels (reciprocal centimeter) are listed. 1 H-NMR spectra were recorded at 400 MHz on Bruker amx 400 MHz spectrophotometer in CDCl 3 using tetramethyl silane (TMS) as internal standard and 13 C-NMR spectra were recorded at 100 MHz on Bruker amx 400 MHz spectrophotometer in CDCl 3 . Mass spectra were recorded on a VG analytical 7070E instrument equipped with VG 11-250 data acquisition system. Elemental analysis (C, H, and N) were carried out on a Carlo Erba Model 1106 and Perkin Elmer models 240 CHN analyzer. The results are within Ϯ0.4% of the theoretical values.
Unless, otherwise stated all the starting materials and reagents were of high-grade purchased from Aldrich, Fluka and Merck. All the solvents were distilled prior to use.
The general synthetic scheme of the novel compounds 25-30 is furnished in Fig. 1 .
Chemistry Cyclic ketones normally undergo BaeyerVilliger oxidation (oxygen insertion reaction) to yield lactones upon treatment with peracids. [43] [44] [45] When 2,6-diarylpiperidin-4-ones were subjected to Baeyer-Villiger type of reaction by using meta chloroperbenzoic acid (m-CPBA), 1-hydroxy-2,6-diarylpiperidin-4-ones resulted instead of lactones. On treatment with acrylonitrile, substituted tetrahydrothiopyran-4-ones containing active hydrogen underwent cyanoethylation yielding 3-[2-cyanoethoxy] derivatives. 46) In 1-hydroxy-2,6-diarylpiperidin-4-ones, there are active methylenic hydrogens at C 3 and C 5 positions. Hence, expec-tation of cyanoethylation to occur at these positions besides at 1-hydroxyl group is quite normal. However in all the cases specifically the 1-hydroxy group alone underwent cyanoethylation 34, [36] [37] [38] to afford 1-[2-cyanoethoxy]-2,6-diarylpiperidin-4-ones in good yields (60-74%) upon treatment with acrylonitrile in the presence of catalyst Triton B.
Usually cyanoethylation 47, 48) is a base catalyzed reaction and invariably requires an alkaline catalyst. But certain amines are quite exceptional. Oxides, hydroxides, alkoxides, alkali metal hydrides etc. are useful for this purpose. Solubility of the bases in organic solvents should be taken into account. Mono or multiple cyanoethylation depends upon the proper choice of a catalyst with sufficient basicity to remove the labile proton from the compound undergoing cyanoethylation. Triton B is particularly employed here on account of its basicity and its solubility in organic media. Cyanoethylation requires cooling to avoid polymerization of acrylonitrile. Inert solvents like benzene, dioxane, acetonitrile or pyridine can be used to dissolve solid reactants or to moderate the reaction.
2,6-Diarylpiperidin-4-ones (1-6) were prepared by the condensation of appropriate ketones, aldehydes and ammonium acetate in 1 : 2 : 1 ratio.
49)
1-Hydroxy-2,6-diphenylpiperidin-4-one (7) A solution of 2,6-diphenylpiperidin-4-one 1 (0.005 mol) and m-CPBA (0.005 mol) in 40 ml of dry chloroform was stirred for 15 min at 0°C and kept aside for overnight at 20°C. Then the mixture was extracted with chloroform and washed well with 10% sodium bicarbonate solution. The chloroform layer was dried over anhydrous sodium sulphate and distilled off under reduced pressure. Purifications with silicagel column chromatography with 4 : 1 benzene-pet.ether (bp 40-60°C) mixture yielded the product 7. The compounds 8-12 were prepared similarly.
1-(2-Cyanoethoxy)-2,6-diphenylpiperidin-4-one (13) A mixture of 1-hydroxy-2,6-diphenylpiperidin-4-one 7 (0.005 mol) and acrylonitrile (0.005 mol) in 50 ml of 1,4-dioxane was taken in a 100 ml round bottom flask and cooled in an ice-bath. A few crystals of resorcinol were added followed by drop wise addition of Triton B with shaking. Then, the contents were stirred for 9 h at 65-75°C and concentrated. After cooling, the resulting solution was poured over 1 : 3 benzene-pet.ether mixture. The solid obtained was recrystallized from methanol to afford the product 13. The compounds 14-18 were prepared similarly.
1-[2-(Benzimidazol-2-yl)ethoxy]-2,6-diphenylpiperidin-4-one (19)
To a mixture of 1-(2-cyanoethoxy)-2,6-diphenylpiperidin-4-one 13 (0.005 mol) and o-phenylenediamine (0.005 mol), dilute hydrochloric acid (10%) was added with constant shaking. The content of the flask was refluxed on an oil-bath for 12 h. After the addition of 50 ml of water to the reaction mass, it was filtered to remove impurities. To isolate product as a base, the acid solution was treated with aqueous ammonia (15 ml) and then poured into water. The precipitated compound 19 was recrystallized twice from ethanol. The compounds 20 and 21 were prepared similarly.
1-[2-(Benzoxazol-2-yl)ethoxy]-2,6-diphenylpiperidin-4-one (22)
A mixture of 1-(2-cyanoethoxy)-2,6-diphenylpiperidin-4-one 16 (0.005 mol), o-aminophenol (0.005 mol) and dilute hydrochloric acid (10%) was taken in a 250 ml round bottom flask and was allowed to reflux on an oil-bath for 18 h. After cooling, the content in the flask was leached with 100 ml of diethyl ether and the separated ether extract was washed with five 25 ml portions of sodium hydroxide (4 N) solution. The ether layer was separated, dried over calcium chloride and freed of ether by distillation. The solid obtained was recrystallized twice from ethanol to yield the product 22. The compounds 23 and 24 were prepared similarly. -2-yl)ethoxy]-2,6-bis( p-chlorophenyl) To comprehend structure-activity relationship well, numberings of the target compound is shown in Fig. 2 . In Vitro Antibacterial and Antifungal Activity The in vitro activities of the compounds were tested in Sabourauds dextrose broth (SDB) (Hi-media, Mumbai) for fungi and Nutrient broth (NB) (Hi-media, Mumbai) for bacteria by the two-fold serial dilution method. 50) The test compounds were dissolved in DMSO (dimethylsulphoxide) to obtain 1 mg/ml stock solutions. Seeded broth (broth containing microbial spores) was prepared in NB from 24 h old bacterial cultures on nutrient agar (Hi-media, Mumbai) at 37Ϯ1°C while fungal spores from 24 h-7 d old Sabourauds agar (Hi-media, Mumbai) slant cultures were suspended in SDB. The colony forming units (cfu) of the seeded broth were determined by plating technique and adjusted in the range of 10 2 -10 5 cfu/ml. The final inoculum size was 10 5 cfu/ml for antibacterial assay and 1.1-1.5ϫ10 2 cfu/ml for antifungal assay. Testing was performed at pH 7.4Ϯ0.2. 0.2 ml of the solution of test compound was added to 1.8 ml of seeded broth to form the first dilution. One milliliter of this was diluted with a further 1 ml of the seeded broth to give the second dilution and so on till six such dilution were obtained. A set of assay tubes containing only inoculated broth was kept as control and likewise solvent controls were also run simultaneously. The tubes were incubated in BOD incubators at 37Ϯ1°C for bacteria and 28Ϯ1°C for fungi. The minimum inhibitory concentrations (MICs) were recorded by visual observations after 24 h (for bacteria) and 72-96 h (for fungi) of incubation. Penicillin, streptomycin and amphotericin B were used as standards.
1-[2-(Benzimidazol-2-yl)ethoxy]-2,6-diphenylpiperidin-4-one Oxime
(25) 1-[2-(Benzimidazol-2-yl)ethoxy]-2,6- diphenylpiperidin-4-
1-[2-(Benzoxazol

RESULTS AND DISCUSSION
Structure-Activity Relationship Results. Antibacterial Activity All the synthesized novel benzimidazol/benzoxazolylethoxypiperidone oximes were evaluated in vitro for their activity to inhibit the growth of bacterial strains viz. Staphylococcus aureus, Bacillus subtilis, Escherichia coli, Pseudomonas aeruginosa. Penicillin and streptomycin were used as standard drugs whose minimum inhibitory concentration (MIC) values are given in Table 1 . To get clear comprehension over antibacterial activity of the synthesized compounds, these were compared with that of their proceeding compounds having keto functionality as reported by Ramalingan et al. 35, 38) Unlike the compounds having keto functional group, the present series of compounds 25-30, with oxime substitution in place of keto group (compounds 25-30) seems to play a vital role in the antibacterial activity against all the tested organisms. The compounds (with keto functionality) which failed to show activity, exhibited moderate activity against Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus and Bacillus subtilis at a MIC ranging from 100-200 mg/ml due to oximation (compounds 25, 28). Compound 25 significantly inhibits Staphylococcus aureus and Bacillus subtilis bacterial strains at a MIC of 50 mg/ml. Likewise, compound 28 also exhibited a higher activity against Pseudomonas aeruginosa and recorded the same MIC.
Substitution of chloro functionalities at the para position of phenyl rings present at C 2 and C 6 of the heterocyclic moiety in 25 and 28 (compounds 26, 29) enhanced antibacterial activity remarkably.
In the case of benzimidazole derivative having para chloro substituent (compound 26) showed 2-4 fold increase in activity against Bacillus subtilis, Escherichia coli and Pseudomonas aeruginosa while only 50% improvement was observed against Staphylococcus aureus. Moreover, in benzoxazole derivative (compound 29) 2-3 fold enhancement was observed against Staphylococcus aureus, Bacillus subtilis whereas against Escherichia coli and Pseudomonas aeruginosa one fold increase in activity was noted. In general, the para substituted compounds 26 and 29 expressed higher activity against the tested organisms when compared to unsubstituted compounds 25 and 28.
Replacement of chloro functionalities present at the para position of phenyl groups by methoxy groups in 26 and 29 (compounds 27, 30) suppressed the activity against all the tested organisms except Staphylococcus aureus and Escherichia coli against which activity was improved due to this replacement in compounds 26 and 29 respectively.
But, when compared to compound having keto functionality at C 4 , the antibacterial activity of the oximated compound 27 was increased by 50% towards the tested bacterial strains and lies in the range of 12.5-50 mg/ml. Similarly compound 30 exerted the same trend in activity except against Escherichia coli and Pseudomonas aeruginosa for which the activity did not change appreciably.
Antifungal Activity The in vitro antifungal activity of the novel compounds 25-30 was studied against the fungal strains viz. Candida albicans, Candida-6, Candida-51, Aspergillus niger and Aspergillus flavus. Amphotericin B was used as standard drug whose minimum inhibitory concentration (MIC) values are furnished in Table 2 .
To mark the superiority of the synthesized compounds 25-30 with oxime functionality towards antifungal activity, the results are compared with the results 35, 38) of compounds having keto functional group instead of oxime at C 4 of the heterocyclic ring moiety.
The compound 25 yielded by the oximation of the corresponding compound possessing keto group (which failed to exert in vitro antifungal activity even at a maximum concentration of 200 mg/ml towards Aspergillus niger and Aspergillus flavus) exhibited well pronounced activity against Candida-51, Aspergillus niger and Aspergillus flavus in the range of 50-100 mg/ml whereas against Candida-6, the activity was not improved appreciably. Likewise the antifungal activity of compound 28 was also significantly enhanced against Candida-6, Candida-51 and Aspergillus flavus while against Candida albicans and Aspergillus flavus, oximation has no effect and the antifungal potency of the parent compounds having keto function was retained as such. Due to the introduction of chloro functionalities at the para position of the aryl groups at C 2 and C 6 of 25 and 28 (compounds 26, 29) instead of hydrogens, the MIC for the tested organisms decreased by about 50% and lies in the range of 12.5-50 mg/ml whereas for unsubstituted compounds, MIC ranges from 50 to 200 mg/ml. In fact, 2-8 fold increase in antifungal efficacy pertaining to compound 26 was observed particularly against Candida-51, Candida-6 and Candida albicans compared to 25 whereas in the case of compound 29, only one fold increase in activity was observed against all the tested strains with respect to compound 28.
From the observation it is obvious that oximation has significant role in enhancing the antifungal activity of the compounds having keto functional group.
Furthermore, introduction of methoxy functionalities in place of hydrogen present at the para position of phenyl groups at C 2 and C 6 of compounds 25 and 28 (compounds 27, 30) have registered a marked improvement in antifungal activity against all the tested organisms except to compound 30 which exerted the same activity of the compound having unsubstitution at aryl groups against Aspergillus niger.
In fact, unlike chlorine substituted compound (compound 29), the methoxy substituted compound (compound 30) exerted one fold increase in activity against Candida-6 and Aspergillus flavus while against rest of the tested organisms, no change in activity was noted compared to the corresponding ketones.
CONCLUSION
A close examination of the in vitro antibacterial and antifungal activity profile of variety of substituted novel benzimidazol/benzoxazolylethoxypiperidone oximes against the bacterial strains viz., Staphylococcus aureus, Bacillus subtilis, Escherichia coli and Pseudomonas aeruginosa and the fungal strains viz., Candida albicans, Candida-6, Candida-51, Aspergillus niger and Aspergillus flavus respectively provide a better structure-activity correlate, which may be summarized as follows.
In the present series of compounds, oximation of keto group at C 4 of heterocyclic moiety seems to play a vital role in the antibacterial activity against Escherichia coli and antifungal activity against Aspergillus flavus. The above said activity for the respective organisms are significantly higher for oximes (compounds 25-30) than the corresponding ketones. Oximation of benzimidazol/benzoxazolylethoxypiperidones changes requisite characteristics needed for exhibiting better structure-activity correlate. Since, the oxime functionality carries a labile proton, which may in turn a key for suitably tailoring the properties of the compounds in terms of solubility, penetration and binding.
The pharmacological screening studies put evidence that benzimidazolylethoxy piperidone oximes are proved to be superior in exerting a marked antibacterial and antifungal profile than the corresponding benzoxazolylethoxypiperidone oximes. Furthermore, both the set of compounds with chloro functions at the para position of the aryl moieties at C 2 and C 6 positions exhibited an elevated antibacterial and antifungal activity than the corresponding methoxy substituted and unsubstituted compounds. Indeed, these chloro substituted compounds showed a promising biological potency when compared to the standard drug.
Moreover, all the tested compounds expressed a remarkable activity against Escherichia coli and Candida-51.
Thus, in future, this class of novel benzimidazol/benzoxazolylethoxypiperidone oximes may be used as templates to generate better drugs to combat bacterial and fungal infections. Although much facinating biological activity of benzazole nucleus is already known, further explorations are sure to uncover even more interesting and useful activities. It is quite remarkable that benzazole nucleus is finding general acceptance as an essential pharmacophoric group. It is also anticipated that benzazole core will continue to find increasing place in future drugs. 
